Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages
Shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) have earned an average rating of “Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in […]
